1. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population
- Author
-
Xi Li, Chengxian Guo, Ji-Ye Yin, Yi Zheng, Pan Xie, Shi-Kun Liu, Zhao-Qian Liu, Hong-Hao Zhou, Mi Luo, Guoping Yang, Qi Pei, and Jun-Yan Liu
- Subjects
Adult ,Blood Glucose ,Male ,China ,Genotype ,Population ,Cmax ,Tetrazoles ,030204 cardiovascular system & hematology ,Pharmacology ,Polymorphism, Single Nucleotide ,030226 pharmacology & pharmacy ,Losartan ,Young Adult ,03 medical and health sciences ,Cmin ,0302 clinical medicine ,Irbesartan ,Asian People ,Piperidines ,Pharmacokinetics ,medicine ,Humans ,Drug Interactions ,Pharmacology (medical) ,education ,Cells, Cultured ,education.field_of_study ,Dose-Response Relationship, Drug ,Liver-Specific Organic Anion Transporter 1 ,business.industry ,Biphenyl Compounds ,Imidazoles ,Area under the curve ,General Medicine ,Repaglinide ,Healthy Volunteers ,Pharmacodynamics ,Valsartan ,Carbamates ,business ,medicine.drug - Abstract
On account of the potential inhibition of OATP1B1 (organic anion transporting polypeptide) by angiotensin II receptor blockers (ARBs) and the effects of SLCO1B1 (solute carrier organic anion transporter family member) polymorphism, the aim of current study is to assess the impact of ARBs on the pharmacokinetics (PK) and pharmacodynamics (PD) of repaglinide in Chinese healthy volunteers with different SLCO1B1 genotypes. The in vitro study was conducted on irbesartan, valsartan, olmesartan, and losartan by using HEK293 cells transfected with OATP1B1. Data on drug interactions between repaglinide and irbesartan from 21 healthy Chinese-Han male volunteers were collected and analyzed. IC50 from in vitro study suggested irbesartan was the most potent inhibitor of OATP1B1 transporter. Clinical data from single dose of repaglinide indicated SLCO1B1 c.521 T>C polymorphism influenced the PK and PD of repaglinide in healthy Chinese-Han male volunteers. In subjects with SLCO1B1 c.521 TT genotype, irbesartan comedication increased the exposure of repaglinide. In details, the peak plasma concentration [Cmax] increased 84% (P = 0.003) and the area under the curve of plasma concentration 0–8 h [AUC0–8] increased 34% (P = 0.004), while the minimum blood glucose concentration [Cmin] decreased 33.8% (P = 0.005). No significant change was observed in repaglinide exposure in subjects with SLCO1B1 c.521 TC genotype in presence or absence of irbesartan. SLCO1B1 c.521 T>C polymorphism affects the PK of repaglinide in Chinese population. Irbesartan increased repaglinide exposure in subjects with SLCO1B1 c.521 TT genotype, but not SLCO1B1 c.521 TC genotype.
- Published
- 2018